Australian Clinical Labs Limited (ACL.AX)
Australian Clinical Labs Limited operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Clayton, VIC, AU. The stock last traded at $2.34, up 0.86% on the session, giving a market capitalisation of $436.5M. Its beta of 0.81 implies it has historically moved less than the broad market.
Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening. Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services. ACL also performs infectious molecular testing, cardiac diagnostic assessments, functional pathology, veterinary pathology, and commercial drug and alcohol screening. These essential services are supplied to both private and public hospitals throughout the nation. The company was founded in 2020 and maintains its primary operational base in Clayton, Australia.
Australian Clinical Labs Limited is most often compared with the following Healthcare names: